Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
June 29, 2018 08:10 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), a developer of innovative materials as hemostatic and wound care devices, today...
Arch Therapeutics Provides Skin Sensitization Study Status Update
June 26, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, provided...
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
June 15, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, announced...
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
May 15, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Provides Update on Study Initiation and 510(k)
May 08, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics Provides Update on 510(k)
March 12, 2018 16:30 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018
March 05, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application
February 05, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Positive data from a clinical study of patients undergoing dermatologic surgery and treated with the AC5™ was published in the peer-reviewed...
Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018
January 02, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
December 18, 2017 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...